Enclomiphene

Estrogen receptors (ER-alpha and ER-beta) are nuclear receptors expressed throughout the body including in the hypothalamus, pituitary, bone, breast tissue, and CNS. In the male HPG axis, ER-alpha at the hypothalamus and pituitary mediates negative feedback from estradiol (E2) — as E2 rises, it binds ERs and reduces GnRH pulse frequency and amplitude, suppressing LH and FSH production. This is the brake mechanism that prevents testosterone overproduction under normal physiological conditions. Testosterone itself also exerts direct HPG axis negative feedback (via the androgen receptor), but the E2 conversion of testosterone via aromatase provides a significant portion of the HPG feedback in men — which is why aromatase inhibitors also raise LH/FSH and testosterone.

Enclomiphene binds estrogen receptors at the hypothalamus and pituitary with high affinity and acts as an antagonist — occupying the receptor site without activating it and preventing endogenous estradiol from binding. The consequence: the E2 negative feedback signal is blocked. The hypothalamus interprets this as a state of estrogen deficiency and increases GnRH pulse frequency and amplitude. The pituitary responds with increased LH and FSH secretion. LH stimulates testicular Leydig cell testosterone production. FSH stimulates Sertoli cells and supports spermatogenesis. The entire HPG axis activates upstream, and endogenous testosterone production rises through the normal physiological cascade.

TRT provides exogenous testosterone, which satisfies all the body's androgen needs — but by the same negative feedback mechanism, the high circulating testosterone (and its aromatization to E2) suppresses GnRH, LH, and FSH. The testes receive no LH signal, Leydig cell function decreases, testicular size decreases, intratesticular testosterone (which is far higher than serum testosterone under normal HPG drive) falls, and spermatogenesis is impaired or absent. Enclomiphene does the opposite: it activates the upstream signal, maintaining or enhancing LH and FSH throughout treatment. The testes continue functioning as they would without TRT. For men concerned about fertility or long-term testicular function, this mechanistic distinction is clinically significant.

Repros Therapeutics conducted multiple Phase 3 trials of enclomiphene citrate (Androxal) in men with secondary hypogonadism. The landmark trial (NCT01534208): n=499 men with secondary hypogonadism (total testosterone ≤300 ng/dL); enclomiphene 12.5 mg or 25 mg daily vs AndroGel 1.62% testosterone gel; 26-week primary assessment. Results at 26 weeks: enclomiphene 25 mg achieved target testosterone (≥300 ng/dL) in approximately 75-80% of men. Testosterone in the enclomiphene groups rose to the normal range. LH and FSH were maintained or elevated (vs testosterone gel where both fell to suppressed levels). Secondary outcomes: sperm parameters maintained in enclomiphene groups; decreased in the testosterone gel group. This is the defining data that established enclomiphene as a viable alternative to TRT for hypogonadal men concerned about fertility.

Saffati GA, Tatem AJ, Bhatt H, et al. (2024). Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Published in PMC (PMC11491226). This review synthesized the published trial data on both enclomiphene and racemic clomiphene for male hypogonadism. Key findings: both compounds effectively raise testosterone in hypogonadal men via HPG axis stimulation; enclomiphene's more selective ER antagonist profile and shorter half-life produce less zuclomiphene-related accumulation and potentially fewer estrogenic side effects vs racemic clomiphene; efficacy comparable to testosterone replacement in controlled comparisons while preserving LH, FSH, and spermatogenesis.

Hohl A, Chavez MP, Pasqualotto E, et al. (2025). Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Published October 2025 in PMC12510335. Methods: systematic search PubMed, Embase, Cochrane, ClinicalTrials.gov through July 2024; RCTs only; men with baseline TT ≤300 ng/dL; SERM vs placebo, T gel, or HCG. Results: SERM therapy (clomiphene/enclomiphene) significantly improved total testosterone vs placebo (MD: +273.76 ng/dL; 95% CI: 191.87-355.66; p<0.01). No statistically significant difference in total testosterone between SERM therapy and testosterone gel — equivalent testosterone restoration. LH improved significantly vs placebo (+4.66 IU/L; p<0.01). FSH improved significantly vs placebo (+4.59 IU/L; p<0.01). Versus HCG: SERM therapy achieved higher total testosterone than HCG alone. Safety: generally favorable; visual adverse effects and mood changes noted, particularly with racemic clomiphene; attributed largely to zuclomiphene accumulation.

FDA Complete Response Letter, December 2015 (Androxal/enclomiphene NDA): the agency issued a CRL stating that based on recent scientific developments, the Phase 3 study design was no longer adequate to demonstrate clinical benefit and recommended additional Phase 3 trials. The core FDA concern was the surrogate endpoint problem: testosterone levels rising is a laboratory finding, not a patient-experienced outcome. The FDA had recently taken a stricter position on requiring endpoints like improved sexual function, energy, mood, or fertility to demonstrate that testosterone elevation actually benefits the patient — beyond the number on a blood test. The same logic that complicated testosterone gel approvals in this period affected enclomiphene. Repros attempted to design additional studies but discontinued development in 2021 — the commercial investment required for additional Phase 3 after a CRL exceeded what the company could sustain.

Study

Grade

Key Finding

Phase 3 Androxal trials (multiple, ~2010-2015, Repros; NCT01534208 anchor)

A

75-80% of men normalized testosterone with enclomiphene 25 mg; LH/FSH maintained; sperm parameters preserved (vs testosterone gel which suppressed all); basis for NDA

Saffati 2024 (PMC11491226; systematic review)

A

Enclomiphene and clomiphene effective for male hypogonadism; enclomiphene superior isomer profile (less zuclomiphene accumulation); equivalent efficacy to TRT with fertility preservation

Hohl 2025 (PMC12510335; meta-analysis of RCTs through July 2024)

A

SERM therapy: TT +273.76 ng/dL vs placebo (p<0.01); LH +4.66 IU/L; FSH +4.59 IU/L; no significant difference vs T gel for TT; SERM > HCG alone for TT; fertility parameters maintained

FDA CRL December 2015

N/A

Testosterone elevation insufficient surrogate; additional Phase 3 required; development discontinued 2021

Enclomiphene is the pure trans isomer of clomiphene; Clomid is a racemic mixture of enclomiphene (50%) + zuclomiphene (50%). They share the enclomiphene mechanism but racemic clomiphene adds the zuclomiphene isomer that accumulates over weeks of daily dosing and produces estrogenic side effects in men. A man taking Clomid 25 mg/day is taking 12.5 mg enclomiphene + 12.5 mg zuclomiphene per day — and with each passing week, zuclomiphene serum levels rise toward 3-10x the enclomiphene level due to its slow clearance. The pharmacological profiles diverge significantly with duration of use. This is not a minor distinction for men who experience visual or mood side effects on Clomid — those symptoms are predominantly a zuclomiphene problem, not an enclomiphene problem.

Enclomiphene is not FDA-approved for any indication. Clomiphene citrate (Clomid) is FDA-approved for ovulation induction in women — not for male hypogonadism. Enclomiphene (Androxal) received a Complete Response Letter in December 2015 and development was discontinued in 2021. The distinction matters for prescribing: a physician prescribing clomiphene to a man for hypogonadism is prescribing an FDA-approved drug (racemic clomiphene) off-label. A physician prescribing enclomiphene specifically is prescribing an investigational drug or a compounded preparation — a different regulatory status.

The 2025 meta-analysis (Hohl et al.) found no statistically significant difference in total testosterone between SERM therapy and testosterone gel — a meaningful finding. However, the mean testosterone increase with SERM therapy was approximately +274 ng/dL from baseline hypogonadal levels. This brings most men from the hypogonadal range into the lower-normal range. Testosterone gel and injectable TRT can be titrated to any target testosterone level — they are not limited by the physiological ceiling of how much testosterone the HPG axis will produce in response to enclomiphene's ER blockade. For men seeking very high-normal or supraphysiological testosterone, enclomiphene cannot match TRT. For men with secondary hypogonadism seeking restoration to the normal physiological range while preserving fertility, enclomiphene is a pharmacologically valid alternative.

Symptom improvement from testosterone restoration is complex and individual — and is partially the reason the FDA rejected the enclomiphene NDA. The FDA's concern: testosterone levels are a surrogate endpoint. Not all men with low testosterone have symptoms; not all men whose testosterone normalizes experience symptom improvement. The Phase 3 enclomiphene trials showed testosterone normalization, not necessarily equivalent symptomatic improvement to TRT on all measures. Sexual function, libido, energy, mood, and body composition changes from enclomiphene vs TRT have not been definitively compared in well-powered, head-to-head controlled trials.

Visual disturbances are the most clinically important CNS side effect associated with the clomiphene class. Reported effects: blurred vision, light sensitivity (photophobia), visual after-images (traces of objects after looking away), 'floaters,' and in rare severe cases, visual field loss. These effects are attributed to estrogen receptor activity in the retinal pigment epithelium — zuclomiphene's partial ER agonism at retinal ER is the suspected mechanism. Crucially: these visual effects appear to be predominantly a zuclomiphene-related phenomenon. The enclomiphene Phase 3 trials with the pure trans isomer showed lower rates of visual adverse events compared to racemic clomiphene. However, visual side effects must be monitored in any enclomiphene/clomiphene user — at onset, report any visual changes to the prescribing physician immediately; discontinue if significant visual disturbances develop.

Mood effects including irritability, anxiety, emotional lability, and mood dysregulation have been reported with clomiphene use in men. Again, these are attributed to zuclomiphene's estrogenic effects at CNS estrogen receptors — a partial agonist signal in CNS circuits that normally process estradiol can produce dysphoric effects, particularly when estradiol levels are simultaneously altered by the antagonist effect of enclomiphene on HPG feedback. Pure enclomiphene users report fewer mood effects than clomiphene users in clinical experience, consistent with the isomer hypothesis. Men with history of mood disorders should monitor carefully during any SERM therapy.

The enclomiphene Phase 3 clinical trials established the dose range: 12.5 mg and 25 mg oral daily. The 25 mg dose produced superior testosterone normalization rates (~75-80% to ≥300 ng/dL) vs 12.5 mg. Community and compounding protocols typically use 12.5-25 mg/day, often starting at 12.5 mg to assess response and tolerability before stepping up to 25 mg. Compared to racemic clomiphene: clomiphene 25-50 mg used in male hypogonadism provides 12.5-25 mg enclomiphene plus 12.5-25 mg zuclomiphene — so 25 mg clomiphene ≈ 12.5 mg enclomiphene equivalent dose for the active isomer alone.

Protocol

Dose

Notes

Standard enclomiphene start

12.5 mg oral once daily

Morning with food; assess testosterone response at 6-8 weeks

Standard enclomiphene maintenance

25 mg oral once daily

Typical maintenance dose based on Phase 3 data; 75-80% normalize testosterone

Racemic clomiphene (off-label, widely used)

12.5-25 mg oral every other day to daily

Equivalent enclomiphene content ~6.25-12.5 mg; zuclomiphene accumulates; preferred by many prescribers due to availability

PCT after anabolic cycle

25-50 mg/day × 4-6 weeks

Often combined with nolvadex (tamoxifen); SERM PCT is standard community practice

Testosterone (total and free), LH, FSH: baseline and at 6-8 weeks to confirm HPG axis stimulation. Estradiol (E2): should rise with testosterone; monitor to ensure not excessively suppressed (the ER antagonism doesn't affect aromatase activity directly, but E2 should be in range). Semen analysis: if fertility preservation is the primary concern, baseline and at 3-6 months. Visual symptoms: any visual disturbances → discontinue and seek ophthalmology review. CBC and metabolic panel: standard monitoring for any hypogonadism treatment.

• Secondary hypogonadism + fertility concern: enclomiphene 12.5-25 mg/day; first-line consideration over TRT; preserves LH, FSH, spermatogenesis; monitoring includes testosterone, LH/FSH, E2, semen analysis if needed.
• Secondary hypogonadism + no fertility concern: TRT remains more predictable for testosterone titration; enclomiphene is valid alternative especially for men wanting to avoid exogenous hormones and preserve HPG axis integrity.
• PCT after anabolic steroid or SARM cycle: 25-50 mg/day × 4-6 weeks; standard SERM PCT; racemic clomiphene acceptable if enclomiphene unavailable, at lower effective dose with zuclomiphene awareness.
• Choosing enclomiphene vs clomiphene: enclomiphene is pharmacologically superior (no zuclomiphene accumulation); racemic clomiphene is widely available off-label as Clomid; if using clomiphene for the enclomiphene effect, lower doses reduce zuclomiphene exposure.
• Monitoring: testosterone, LH, FSH at 6-8 weeks; E2 to confirm balance; visual symptom check at every visit; any visual changes → discontinue immediately; ophthalmology consultation if visual effects persist.

— End of Enclomiphene —

THE PEPTIDE BIBLE | Enclomiphene | For Research & Educational Purposes Only